Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score–Matched Real-World Study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.738 95% CI 0.675–0.806Authors' conclusion
In this large propensity score-matched real-world cohort of patients with HFpEF, liraglutide was associated with significantly lower risks of mortality, heart failure events, hospitalization, stroke, and hypoglycemia than dulaglutide at 1 and 5 years.
Study context
- Population
- Adults with heart failure with preserved ejection fraction (HFpEF) newly initiating liraglutide or dulaglutide, TriNetX US Collaborative Network
- Participants
- 99,683 adults36,851 matched pairs
- Exposure
- Liraglutide vs dulaglutide
- Liraglutiden = 37,386
- Dulaglutiden = 62,297reference
- Outcome
- All-cause mortality
- Follow-up
- 1 year
Methodological detailsmulticenter, propensity-score matched, real-world, TriNetX US Collaborative Network
- Multicenter
- Propensity-score matched
- Real-world
- TriNetX US Collaborative Network
Main finding
As reported in the abstract
Hazard ratio
0.738
95% CI 0.675–0.806
P < 0.0001
Liraglutidevs Dulaglutide
HR 0.738 (95% CI 0.675–0.806); P < 0.0001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Acute HF events · 1 yearPropensity-score matched | 0.862 (0.830–0.894) | P < 0.0001 | |
| All-cause hospitalization · 1 yearPropensity-score matched | 0.927 (0.901–0.954) | P < 0.0001 | |
| Stroke · 1 yearPropensity-score matched | 0.900 (0.863–0.939) | P < 0.0001 | |
| Hypoglycemia · 1 yearPropensity-score matched | 0.891 (0.808–0.983) | P = 0.021 | |
| 0.512Hazard ratio (log scale) |
| Outcome | HR |
|---|---|
| All-cause mortality · 5 yearsPropensity-score matched | 0.775 |
| Acute HF · 5 yearsPropensity-score matched | 0.820 |
| Stroke · 5 yearsPropensity-score matched | 0.848 |
MI · 5 years
- MI reduction emerged only at 5 years
- Propensity-score matched
Safety
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Hypoglycemia · 1 year | 0.891 (0.808–0.983) | P = 0.021 | |
| 0.512Hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score–Matched Real-World Study. Endocr Pract. Published 25 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →